Relmada Therapeutics Inc

NASDAQ RLMD

Data sourced from

and

Download Data

Relmada Therapeutics Inc Revenue Per Share for the quarter ending March 31, 2024: USD 0.00

Relmada Therapeutics Inc Revenue Per Share is USD 0.00 for the quarter ending March 31, 2024, a 0.00% change year over year. Revenue per share measures the amount of revenue generated by a company per outstanding share. It is calculated by dividing the revenue by the number of outstanding shares (weighted average). This ratio provides insights into the company's revenue generation on a per-share basis. A higher revenue per share indicates stronger revenue performance and potentially higher value per share for investors.

Relmada Therapeutics Inc Revenue Per Share for the quarter ending March 31, 2023 was USD 0.00, a 0.00% change year over year.
Relmada Therapeutics Inc Revenue Per Share for the quarter ending March 31, 2022 was USD 0.00, a 0.00% change year over year.
Relmada Therapeutics Inc Revenue Per Share for the quarter ending March 31, 2021 was USD 0.00, a 0.00% change year over year.
Relmada Therapeutics Inc Revenue Per Share for the quarter ending March 31, 2020 was USD 0.00, a 0.00% change year over year.

NASDAQ: RLMD

Relmada Therapeutics Inc

CEO	Dr. Sergio Traversa M.B.A., MBA, Pharm.D., PharmD
IPO Date	Oct. 9, 2014
Location	United States
Headquarters	2222 Ponce de Leon Boulevard, Coral Gables, FL, United States, 33134
Employees	20
Sector	Healthcare
Industry	Biotechnology

Description

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system diseases (CNS) and other disorders in the United States. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a N-methyl-D-aspartate receptor antagonist which is in phase 3 clinical trial for the adjunctive or monotherapy treatment of major depressive disorder. The company is headquartered in Coral Gables, Florida.

Key trends